Evidence map›Paper›PMID 38566387›Full record

ReviewCurrent pharmaceutical biotechnology2025

A Comprehensive Review on Nanoparticles as Drug Delivery System and Their Role for Management of Hypertension.

Prerna, Dinesh Chandra Bhatt, Khalid Basir Mir, Vikash Kumar, Sandeep Rathor

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

PrernaDepartment of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University) Mullana, Ambala, 133207, Haryana, India.
Dinesh Chandra BhattDepartment of Pharmaceutical Sciences, Guru Jambheswar University of Sciences and Technology, Hisar, Haryana, 125001, India.
Khalid Basir MirSchool of Medical and Allied Sciences, K. R. Mangalam University, Sohna Road, Gurgaon, Haryana, 122103, India.
Vikash KumarDK Pharma College, Dhani T. Bad, Rewari, Haryana, 123411, India.
Sandeep RathorDepartment of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University) Mullana, Ambala, 133207, Haryana, India.
Maharishi Markandeshwar University, Mullana · INGuru Jambheshwar University of Science and Technology · INHindu College of Pharmacy · INKR Mangalam University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current global epidemic of hypertension is not a disease in and of itself but rather a significant risk factor for serious cardiovascular conditions such as peripheral artery disease, heart failure, myocardial infarction, and stroke. Although many medications that work through various mechanisms of action are available on the market in conventional formulations to treat hypertension, these medications face significant difficulties with their bioavailability, dosing, and associated side effects, which significantly reduces the effectiveness of their therapeutic interventions. Numerous studies have shown that nanocarriers and nanoformulations can minimize the toxicity associated with high doses of the drug while greatly increasing the drug's bioavailability and reducing the frequency of dosing. This review sheds light on the difficulties posed by traditional antihypertensive formulations and highlights the necessity of oral nanoparticulate systems to solve these issues. Because hypertension has a circadian blood pressure pattern, chronotherapeutics can be very important in treating the condition. On the other hand, nanoparticulate systems can be very important in managing hypertension.

Indexed as

Antihypertensive AgentsDrug Delivery SystemsHypertensionNanoparticle Drug Delivery SystemNanoparticlesAnimalsHumansAntihypertensive AgentsNanoparticle Drug Delivery Systemapplications.dendrimersdrug delivery systemshypertensionliposomesnano-emulsionsPolymeric nanoparticles

Identifiers

PMID38566387
OpenAlexW4393866524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.